Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.

The epidemic of extended-spectrum-β-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx.

Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, Nordstrom L, Billig M, Chattopadhyay S, Stegger M, Andersen PS, Pearson T, Riddell K, Rogers P, Scholes D, Kahl B, Keim P, Sokurenko EV.

MBio. 2013 Dec 17;4(6):e00377-13. doi: 10.1128/mBio.00377-13.

2.

Trends of extended-spectrum β-lactamase-producing Escherichia coli sequence type 131 and its H30 subclone in a French hospital over a 15-year period.

Sauget M, Cholley P, Vannier A, Thouverez M, Nicolas-Chanoine MH, Hocquet D, Bertrand X.

Int J Antimicrob Agents. 2016 Dec;48(6):744-747. doi: 10.1016/j.ijantimicag.2016.09.023. Epub 2016 Nov 4.

PMID:
27836379
3.

Genomic and Functional Portrait of a Highly Virulent, CTX-M-15-Producing H30-Rx Subclone of Escherichia coli Sequence Type 131.

Ranjan A, Shaik S, Hussain A, Nandanwar N, Semmler T, Jadhav S, Wieler LH, Ahmed N.

Antimicrob Agents Chemother. 2015 Oct;59(10):6087-95. doi: 10.1128/AAC.01447-15. Epub 2015 Jul 20.

4.

CTX-M-27- and CTX-M-14-producing, ciprofloxacin-resistant Escherichia coli of the H30 subclonal group within ST131 drive a Japanese regional ESBL epidemic.

Matsumura Y, Johnson JR, Yamamoto M, Nagao M, Tanaka M, Takakura S, Ichiyama S; Kyoto–Shiga Clinical Microbiology Study Group; Kyoto-Shiga Clinical Microbiology Study Group.

J Antimicrob Chemother. 2015;70(6):1639-49. doi: 10.1093/jac/dkv017. Epub 2015 Feb 16.

PMID:
25687644
5.

Escherichia coli Sequence Type 131 H30 Is the Main Driver of Emerging Extended-Spectrum-β-Lactamase-Producing E. coli at a Tertiary Care Center.

Johnson JR, Johnston B, Thuras P, Launer B, Sokurenko EV, Miller LG.

mSphere. 2016 Nov 23;1(6). pii: e00314-16. eCollection 2016 Nov-Dec.

6.

Evolutionary History of the Global Emergence of the Escherichia coli Epidemic Clone ST131.

Stoesser N, Sheppard AE, Pankhurst L, De Maio N, Moore CE, Sebra R, Turner P, Anson LW, Kasarskis A, Batty EM, Kos V, Wilson DJ, Phetsouvanh R, Wyllie D, Sokurenko E, Manges AR, Johnson TJ, Price LB, Peto TE, Johnson JR, Didelot X, Walker AS, Crook DW; Modernizing Medical Microbiology Informatics Group (MMMIG).

MBio. 2016 Mar 22;7(2):e02162. doi: 10.1128/mBio.02162-15.

7.

Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans.

Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, Kuskowski MA, Tchesnokova V, Sokurenko EV, Johnson JR; VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators.

Clin Infect Dis. 2013 Nov;57(9):1256-65. doi: 10.1093/cid/cit503. Epub 2013 Aug 6.

8.

A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131.

Banerjee R, Johnson JR.

Antimicrob Agents Chemother. 2014 Sep;58(9):4997-5004. doi: 10.1128/AAC.02824-14. Epub 2014 May 27. Review.

9.

Molecular epidemiology and virulence of Escherichia coli O16:H5-ST131: comparison with H30 and H30-Rx subclones of O25b:H4-ST131.

Dahbi G, Mora A, Mamani R, López C, Alonso MP, Marzoa J, Blanco M, Herrera A, Viso S, García-Garrote F, Tchesnokova V, Billig M, de la Cruz F, de Toro M, González-López JJ, Prats G, Chaves F, Martínez-Martínez L, López-Cerezo L, Denamur E, Blanco J.

Int J Med Microbiol. 2014 Nov;304(8):1247-57. doi: 10.1016/j.ijmm.2014.10.002. Epub 2014 Oct 14.

PMID:
25455219
10.

Prevalence and characteristics of Escherichia coli sequence type 131 and its H30 and H30Rx subclones: a multicenter study from Korea.

Kim SY, Park YJ, Johnson JR, Yu JK, Kim YK, Kim YS.

Diagn Microbiol Infect Dis. 2016 Feb;84(2):97-101. doi: 10.1016/j.diagmicrobio.2015.10.016. Epub 2015 Oct 28.

PMID:
26643062
11.

Temporal trends in antimicrobial resistance and virulence-associated traits within the Escherichia coli sequence type 131 clonal group and its H30 and H30-Rx subclones, 1968 to 2012.

Olesen B, Frimodt-Møller J, Leihof RF, Struve C, Johnston B, Hansen DS, Scheutz F, Krogfelt KA, Kuskowski MA, Clabots C, Johnson JR.

Antimicrob Agents Chemother. 2014 Nov;58(11):6886-95. doi: 10.1128/AAC.03679-14. Epub 2014 Sep 8.

12.

Characterization of extended-spectrum-beta-lactamase-producing Escherichia coli strains involved in maternal-fetal colonization: prevalence of E. coli ST131.

Birgy A, Mariani-Kurkdjian P, Bidet P, Doit C, Genel N, Courroux C, Arlet G, Bingen E.

J Clin Microbiol. 2013 Jun;51(6):1727-32. doi: 10.1128/JCM.03255-12. Epub 2013 Mar 20.

13.

Molecular epidemiology of Escherichia coli producing extended-spectrum {beta}-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15.

Blanco M, Alonso MP, Nicolas-Chanoine MH, Dahbi G, Mora A, Blanco JE, López C, Cortés P, Llagostera M, Leflon-Guibout V, Puentes B, Mamani R, Herrera A, Coira MA, García-Garrote F, Pita JM, Blanco J.

J Antimicrob Chemother. 2009 Jun;63(6):1135-41. doi: 10.1093/jac/dkp122. Epub 2009 Apr 7.

PMID:
19351692
14.
15.

Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States.

Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M.

Clin Infect Dis. 2010 Aug 1;51(3):286-94. doi: 10.1086/653932.

PMID:
20572763
16.

Variation in resistance traits, phylogenetic backgrounds, and virulence genotypes among Escherichia coli clinical isolates from adjacent hospital campuses serving distinct patient populations.

Drawz SM, Porter S, Kuskowski MA, Johnston B, Clabots C, Kline S, Ferrieri P, Johnson JR.

Antimicrob Agents Chemother. 2015 Sep;59(9):5331-9. doi: 10.1128/AAC.00048-15. Epub 2015 Jun 22.

17.

The clinical impact of ST131 H30-Rx subclone in urinary tract infections due to multidrug-resistant Escherichia coli.

Can F, Kurt-Azap Ö, İspir P, Nurtop E, Seref C, Loçlar İ, Aktaş ON, Orhan YC, Ergonul O.

J Glob Antimicrob Resist. 2016 Mar;4:49-52. doi: 10.1016/j.jgar.2015.10.006. Epub 2015 Nov 14.

PMID:
27436393
18.

Molecular epidemiology of Escherichia coli sequence type 131 and its H30/H30-Rx subclones recovered from extra-intestinal infections: first report of OXA-48 producing ST131 clone from Iran.

Hojabri Z, Mirmohammadkhani M, Kamali F, Ghassemi K, Taghavipour S, Pajand O.

Eur J Clin Microbiol Infect Dis. 2017 May 27. doi: 10.1007/s10096-017-3021-9. [Epub ahead of print]

PMID:
28550370
19.

Prevalence of Escherichia coli sequence type 131 and its H30 subclone among E. coli isolates in a French hospital.

Lafolie J, Nicolas-Chanoine MH, Grenouillet F, Hocquet D, Bertrand X.

Int J Antimicrob Agents. 2014 Nov;44(5):466-8. doi: 10.1016/j.ijantimicag.2014.07.016. Epub 2014 Sep 3.

PMID:
25241262
20.

Intensity and Mechanisms of Fluoroquinolone Resistance within the H30 and H30Rx Subclones of Escherichia coli Sequence Type 131 Compared with Other Fluoroquinolone-Resistant E. coli.

Johnson JR, Johnston B, Kuskowski MA, Sokurenko EV, Tchesnokova V.

Antimicrob Agents Chemother. 2015 Aug;59(8):4471-80. doi: 10.1128/AAC.00673-15. Epub 2015 May 18. Erratum in: Antimicrob Agents Chemother. 2015 Sep;59(9):5871.

Supplemental Content

Support Center